NASDAQ$INDV
Indivior Pharmaceuticals Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Indivior reported Q4 2025 total net revenue of $358M, GAAP net income of $102M, and adjusted EBITDA of $142M.
Q4 2025 total net revenue was $358 million with SUBLOCADE net revenue of $252 million (+30% YoY). GAAP net income was $102 million ($0.79 diluted EPS) and non-GAAP net income was $107 million ($0.82 EPS). Adjusted EBITDA was $142 million, a quarterly record.
- Total net revenue $358M.
- SUBLOCADE revenue $252M (+30% YoY).
- GAAP net income $102M; EPS $0.79.
- Record quarterly adjusted EBITDA $142M.
Headline financials
Revenue & EPS history
Indivior · Revenue · Quarterly
$358M
Forward guidance
2026 outlook targets mid-teens SUBLOCADE volume growth and accelerated cash flow.
Tailwinds
- SUBLOCADE dispense units +12% in U.S.
- Operating model transformation lowering cost base.
Headwinds
- Opioid addiction market competition.
- Payer access and Medicaid dynamics.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q4 2025
+7.2%
Avg return
Earnings day
+12.4%
Avg return
5 days after
+871.4%
Avg return
30 days after
73%
8 / 11 earnings
Positive
+24.4%
Q4 2023
Best reaction
-16.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | +15.9% | — | |
| Q4 2025 | +0.2% | -8.2% | -13.9% | |
| Q3 2025 | +15.4% | +26.8% | +33.1% | |
| Q2 2025 | +16.1% | +25.3% | +39.5% | |
| Q1 2025 | +17.3% | +24.3% | +8632.9% | |
| Q3 2024 | +7.0% | +7.0% | +27.1% | |
| Q2 2024 | +19.2% | +8.3% | -5.4% | |
| Q1 2024 | -7.0% | +25.5% | +13.1% | |
| Q4 2023 | +24.4% | +27.1% | +19.3% | |
| Q3 2023 | -16.0% | -9.4% | -21.5% | |
| Q2 2023 | -5.4% | -6.8% | -10.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro